earnings
confidence high
sentiment positive
materiality 0.85
Gilead Q4 revenue $7.1B (-4% YoY); FY23 non-GAAP EPS $6.72; guides FY24 product sales $27.1-27.5B
GILEAD SCIENCES, INC.
2023-FY EPS reported
$4.50
revenue$27,116,000,000
- Q4 2023 GAAP EPS $1.14 (down from $1.30); non-GAAP EPS $1.72 (up from $1.67).
- Full-year 2023 product sales $26.9B, flat YoY; HIV sales up 6% to $18.2B; Biktarvy up 14% to $11.8B.
- Oncology sales up 37% for full year; Cell Therapy $1.9B (+28%); Trodelvy $1.1B (+56%).
- Veklury sales fell 44% to $2.2B in FY23; Q4 Veklury $720M (-28% YoY).
- FY24 guidance: product sales $27.1-27.5B, Veklury ~$1.3B, GAAP EPS $5.15-5.55, non-GAAP EPS $6.85-7.25.